Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenifer Abbott

Physician Assistant, Surgical Havre De Grace, MD Physician Assistant

NPI 1225136161 CMS profile 11230205

930 Revolution St, Havre De Grace, MD 21078

Open in the dashboard

General payments

$8,921

320 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenifer Abbott of Havre De Grace, MD is reported in the CMS Open Payments database as having received $8,921 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,928 64
2024 General $2,287 103
2023 General $2,027 74
2022 General $1,768 46
2021 General $911 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenifer Abbott
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Jenifer Abbott were reported at $1,928. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Jenifer Abbott Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $911 $111 $36–$285 $132
2022 $1,768 $126 $44–$350 $149
2023 $2,027 $137 $47–$355 $160
2024 $2,287 $146 $49–$384 $164
2025 $1,928 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,857 24 payments
  2. AbbVie, Inc. $1,327 61 payments
  3. Novartis Pharmaceuticals Corporation $906 67 payments
  4. Janssen Biotech, Inc. $834 34 payments
  5. Dermavant Sciences, Inc. $715 22 payments
  6. Incyte Corporation $481 12 payments
  7. E.R. Squibb & Sons, L.L.C. $409 16 payments
  8. UCB, Inc. $407 20 payments
  9. LEO Pharma Inc. $368 6 payments
  10. Organon LLC $263 8 payments
  11. Other $1,353 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,716 316 payments
  2. Consulting Fee $923 1 payment
  3. Education $282 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,582 16 payments
  2. VTAMA $762 25 payments
  3. RINVOQ $709 28 payments
  4. TREMFYA $590 23 payments
  5. SKYRIZI $499 25 payments
  6. OPZELURA $481 12 payments
  7. COSENTYX $409 32 payments
  8. SOTYKTU $409 16 payments
  9. SIMPONI ARIA $369 21 payments
  10. STELARA $369 21 payments
  11. Other $3,810 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

952

Median for Physician Assistant: 241

Drug cost

$658,768

Median for Physician Assistant: $4,110

Branded share of claims

10.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 18 $360,552
Otezla Apremilast Brand 40 $219,620
Dupixent Pen Dupilumab Brand 12 $47,656
Doxycycline Hyclate Generic 37 $8,319
Ketoconazole Generic 208 $3,586
Fluorouracil Generic 40 $2,669
Ivermectin Generic 11 $2,665
Clindamycin Phosphate Generic 48 $2,649
Clobetasol Propionate Generic 48 $2,649
Metronidazole Generic 26 $1,442

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$192,277

Of which drugs: $7,744

Medicare patients

968

Average age 74

Services billed

3,898

589 women, 379 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 24%
Chronic kidney disease 18%
Cancer 17%
Depression 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 13 25 $7,733

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $402
$402 — —
TREMFYA
  • Janssen Biotech, Inc. $379
$379 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $260
$260 — —
RINVOQ
  • AbbVie, Inc. $240
$240 — —
Bimzelx
  • UCB, Inc. $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record